Safety of High-dose Intravenous Eptifibatide as an Adjunct to Internal Carotid Artery Angioplasty and Stent Placement: A Prospective Registry

Neurosurgery

Volumn 54, Issue 2, 2004, Pages 307-317

  Qureshi, Adnan I ^a,b,c   Siddiqui, Amir M ^b   Hanel, Ricardo A ^a   Xavier, Andrew R ^b   Kim, Stanley H ^a   Kirmani, Jawad F ^a   Boulos, Alan S ^a   Hopkins, L Nelson ^a   Thomas, Jeffrey E ^d   Higashida, Randall T ^d   Rosenwasser, Robert H ^d   Duckwiler, Gary R ^d  

^a UNIVERSITY AT BUFFALO   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

^d NONE

Author keywords

Angioplasty; Carotid stenosis; Cerebral infarction; Eptifibatide; Heparin; Stent placement; Transient ischemic attack

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PHENYTOIN; PLACEBO; TIROFIBAN;

ADULT; AGED; ANGIONEUROTIC EDEMA; ANGIOPLASTY; ARTICLE; BLOOD CLOTTING PARAMETERS; BRAIN HEMORRHAGE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FEMORAL ARTERY; GENERALIZED EPILEPSY; HEMOGLOBIN DETERMINATION; HUMAN; INTERNAL CAROTID ARTERY OCCLUSION; MALE; NEUROTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REGISTER; SEPSIS; STENT; THROMBOCYTE AGGREGATION;

EID: 10744229794     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000103224.90865.2E     Document Type: Article

References (33)

1. Anonymous: Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II-Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 349:1422-1428, 1997.
2. Biller J, Feinberg WM, Castaldo JE, Whittemore AD, Harbaugh RE, Dempsey RJ, Caplan LR, Kresowik TF, Matchar DB, Toole J, Easton JD, Adams HP Jr, Brass LM, Hobson RW II, Brott TG, Stemau L: Guidelines for carotid endarterectomy: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 29:554-562, 1998.
3. Diethrich EB, Ndiaye M, Reid DB: Stenting in the carotid artery: Initial experience in 110 patients. J Endovasc Surg 3:42-62, 1996.
4. Gagne PJ, Matchett J, MacFarland D, Hauer-Jensen M, Barone GW, Eidt JF, Barnes RW: Can the NASCET technique for measuring carotid stenosis be reliably applied outside the trial? J Vasc Surg 24:449-456, 1996.
5. Gil-Peralta A, Mayol A, Marcos JR, Gonzalez A, Ruano J, Boza F, Duran F: Percutaneous transluminal angioplasty of the symptomatic atherosclerotic carotid arteries: Results, complications, and follow-up. Stroke 27:2271-2273, 1996.
6. Harker LA: Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am J Cardiol 60:20B-28B, 1987.
7. Harrington RA, Kleiman NS, Kottke-Marchant K, Lincoff AM, Tcheng JE, Sigmon KN, Joseph D, Rios G, Trainor K, Rose D, Greenberg CS, Kitt MM, Topol EJ, Califf RM: Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 76:1222-1227, 1995.
8. Hobson RW II: Carotid angioplasty-stent: Clinical experience and role for clinical trials. J Vasc Surg 33[2 Suppl]:S117-S123, 2001.
9. Lefkovits J, Plow EF, Topol EJ: Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 332:1553-1559, 1995.
10. Mathur A, Roubin GS, Iyer SS, Piamsonboon C, Liu MW, Gomez CR, Yadav JS, Chastain HD, Fox LM, Dean LS, Vitek JJ: Predictors of stroke complicating carotid artery stenting. Circulation 97:1239-1245, 1998.
11. Ohki T, Veith O, Grenell S, Lipsitz EC, Gargiulo N, McKay J, Valladares J, Suggs WD, Kazmi M: Initial experience with cerebral protection devices to prevent embolization during carotid artery stenting. J Vasc Surg 36:1175-1185, 2002.
12. Phillips DR, Charo IF, Parise LV, Fitzgerald LA: The platelet membrane glycoprotein IIb-IIIa complex. Blood 71:831-843, 1988.
13. PURSUIT Trial Investigators: Inhibition of platelet glycoprotein IIb/ IIIa with eptifibatide in patients with acute coronary syndromes: Platelet Glycoprotein IIb/IIIa in Unstable Angina-Receptor Suppression Using Integrilin Therapy. N Engl J Med 339:436-443, 1998.
14. Qureshi AI: Adjunctive use of platelet glycoprotein IIb/IIIa inhibitors for carotid angioplasty and stent placement: Time to say good bye? J Endovasc Ther 10:42-44, 2003 (comment).
15. Qureshi AI, Ali Z, Suri MF, Kim SH, Fessler RD, Ringer AJ, Guterman LR, Hopkins LN: Open-label phase I clinical study to assess the safety of intravenous eptifibatide in patients undergoing internal carotid artery angioplasty and stent placement. Neurosurgery 48:998-1005, 2001.
16. Qureshi AI, Luft AR, Janardhan V, Suri MF, Sharma M, Lanzino G, Wakhloo AK, Guterman LR, Hopkins LN: Identification of patients at risk for periprocedural neurological deficits associated with carotid angioplasty and stenting. Stroke 31:376-382, 2000.
17. Qureshi AI, Luft AR, Sharma M, Guterman LR, Hopkins LN: Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: Part 1. Pathophysiological and pharmacological features. Neurosurgery 46:1344-1359, 2000.
18. Qureshi AI, Luft AR, Sharma M, Guterman LR, Hopkins LN: Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: Part II. Clinical aspects and recommendations. Neurosurgery 46:1360-1376, 2000.
19. Qureshi AI, Saad M, Zaidat OO, Suarez JI, Alexander MJ, Fareed M, Suri K, All Z, Hopkins LN: Intracerebral hemorrhages associated with neurointerventional procedures using a combination of antithrombotic agents including abciximab. Stroke 33:1916-1919, 2002.
20. Qureshi AL, Suri MF, Ali Z, Kim SH, Lanzino G, Fessler RD, Ringer AJ, Guterman LR, Hopkins LN: Carotid angioplasty and stent placement: A prospective analysis of perioperative complications and impact of intravenously administered abciximab. Neurosurgery 50:466-475, 2002.
21. Qureshi AI, Suri MF, Khan J, Fessler RD, Guterman LR, Hopkins LN: Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty: Preliminary experience. Neurosurgery 46:1316-1325, 2000.
22. Qureshi AI, Suri MF, New G, Wadsworth DC Jr, Dulin J, Hopkins LN: Multicenter study of the feasibility and safety of using the Memotherm carotid arterial stent for extracranial carotid artery stenosis. J Neurosurg 96:830-836, 2002.
23. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML: Thrombolysis in Myocardial Infarction (TIMI) Trial: Phase I. Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11:1-11, 1988.
24. Scarborough RM, Naughton MA, Teng W, Rose JW, Phillips DR, Nannizzi L, Arfsten A, Campbell AM, Charo IF: Design of potent and specific integrin antagonists: Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 268:1066-1073, 1993.
25. Scarborough RM, Rose JW, Hsu MA, Phillips DR, Fried VA, Campbell AM, Nannizzi L, Charo IF: Barbourin: A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem 266:9359-9362, 1991.
26. Schluter M, Tubler T, Mathey DG, Schofer J: Feasibility and efficacy of balloon-based neuroprotection during carotid artery stenting in a single-center setting. J Am Coll Cardiol 40:890-895, 2002.
27. Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS, Coller BS: Rapid platelet-function assay: An automated and quantitative cartridge-based method. Circulation 99:620-625, 1999.
28. Steele PM, Chesebro JH, Stanson AW, Holmes DR Jr, Dewanjee MK, Badimon L, Fuster V: Balloon angioplasty: Natural history of the pathophysiological response to injury in a pig model. Circ Res 57:105-112, 1985.
29. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ, Miller JA, Joseph DM, Sigmon KN, Kitt MM, du Mée CP, Califf RM, Topol EJ; the IMPACT Investigators: Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. Circulation 91:2151-2157, 1995.
30. Tcheng JE, Talley JD, O'Shea JC, Gilchrist IC, Kleiman NS, Grines CL, Davidson CJ, Lincoff AM, Califf RM, Jennings LK, Kitt MM, Lorenz TJ: Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). Am J Cardiol 88:1097-1102, 2001.
31. Verstraete M: Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development. Circulation 101:E76-E80, 2000.
32. Whitlow PL, Lylyk P, Londero H, Mendiz OA, Mathias K, Jaeger H, Parodi J, Schonholz C, Milei J: Carotid artery stenting protected with an emboli containment system. Stroke 33:1308-1314, 2002.
33. Wilentz JR, Sanborn TA, Haudenschild CC, Valeri CR, Ryan TJ, Faxon DP: Platelet accumulation in experimental angioplasty: Time course and relation to vascular injury. Circulation 75:636-642, 1987.